Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 6/2017

01-12-2017 | Original Paper

Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy

Authors: Makiko Katagiri, Jun Shoji, Satoshi Kato, Shigehiko Kitano, Yasuko Uchigata

Published in: International Ophthalmology | Issue 6/2017

Login to get access

Abstract

Purpose

We investigated the relationship between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and vascular endothelial growth factor (VEGF) and renal function, and correlations between vitreous sRAGE levels and proliferative diabetic retinopathy (PDR) activity.

Methods

We examined 33 eyes from 33 patients with diabetes mellitus who underwent a vitrectomy (eight patients in the non-PDR [NPDR] group and 25 in the PDR group). Serum creatinine levels and estimated glomerular filtration rate (eGFR) were measured and classified according to the chronic kidney disease (CKD)-staging method. Enzyme-linked immunosorbent assay (ELISA) was performed to quantify vitreous sRAGE and VEGF levels.

Results

Vitreous sRAGE levels were significantly higher in PDR group compared to NPDR group (p = 0.00003). Vitreous sRAGE levels were significantly higher in patients with CKD stage 5 (end-stage renal failure or hemodialysis) than in patients with CKD stage 1 or 2 (p < 0.01) and 3 or 4 (p < 0.05), and were significantly correlated with eGFR (r = − 0.490, p = 0.007) and creatinine levels (r = 0.484, p = 0.006). Within the PDR group, patients with low (<27 pg/mL) sRAGE levels required repeat vitreous surgeries for early postoperative vitreous hemorrhage significantly more frequently than those with high (≥27 pg/mL) sRAGE levels (p = 0.0067).

Conclusions

Vitreous sRAGE levels were significantly correlated with renal function, and low vitreous sRAGE levels in patients with PDR were associated with postoperative vitreous hemorrhage. Vitreous sRAGE may be a useful biomarker for renal dysfunction associated with diabetic retinopathy.
Literature
1.
2.
Lee WJ, Sobrin L, Kang MH, Seong M, Kim YJ, Yi JH, Miller JW, Cho HY (2014) Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression. Eye 28:1119–1125CrossRefPubMedPubMedCentral
3.
Matsuo T (2006) Disappearance of diabetic macular hard exudates after hemodialysis introduction. Acta Med Okayama 60:201–205PubMed
4.
Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87–101CrossRefPubMed
5.
Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279–2299CrossRefPubMed
6.
Yamamoto Y, Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi M, Yamamoto H (2007) Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 77:S30–S40CrossRefPubMed
7.
Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M (2006) TAGE (toxic AGE) theory in diabetic complication. Curr Mol Med 6:351–358CrossRefPubMed
8.
Ai J, Liu Y, Sun JH (2013) Advanced glycation end-products stimulate basic fibroblast growth factor expression in cultured Müller cells. Mol Med Rep 7:16–20CrossRefPubMed
9.
Zong H, Ward A, Madden A, Yong PH, Limb GA, Curis TM, Stitt AW (2010) Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products(RAGE). Diabetologia 53:2656–2666CrossRefPubMed
10.
Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP (2007) Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 48:858–865CrossRefPubMed
11.
Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, Zima T (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47:406–411CrossRefPubMed
12.
Kalousová M, Jáchymová M, Mestek O, Hodková M, Kazderová M, Tesar V, Zima T (2007) Receptor for advanced glycation end products—soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22:2020–2026CrossRefPubMed
13.
Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B (2015) Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease stage 5 patients. Nephrol Dial Transplant 30:84–91CrossRefPubMed
14.
Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK (2009) Association between circulating soluble receptor for advanced glycation end products and atherosclerosis. Diabetes Care 32:1218–1220CrossRefPubMedPubMedCentral
15.
Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler ThrombVasc Biol 25:1032–1037CrossRef
16.
Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J, Astor BC (2013) sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 62:2116–2121CrossRefPubMedPubMedCentral
17.
Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682CrossRefPubMed
18.
Kidney disease: Improving global outcomes (KDIGO) CKD work group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRef
19.
Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan Y-CE, Tsang TC, Stern D (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987–14997PubMed
20.
Takagi H, King GL, Aiello LP (1996) Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 45:1016–1023CrossRefPubMed
21.
Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, Cataldergirmen G, Scarmeas N, Caspersen C, Chang S, Schiff WM, Schmidt AM, Barile GR (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 82:807–815CrossRefPubMed
22.
El-Asrar AM, Nawaz MI, Kangave D, Geboes K, Ola MS, Ahmad S, Al-Shabrawey M (2011) High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis 17:1829–1838PubMedPubMedCentral
23.
Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Hörig H, Hudson BI, Qu W, Weinberg AD, Yan SF, Schmidt AM (2005) The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 46:2916–2924CrossRefPubMed
Metadata
Title
Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy
Authors
Makiko Katagiri
Jun Shoji
Satoshi Kato
Shigehiko Kitano
Yasuko Uchigata
Publication date
01-12-2017
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 6/2017
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-016-0389-y

Other articles of this Issue 6/2017

International Ophthalmology 6/2017 Go to the issue

Original Paper

Effects of alpha-lipoic acid on retinal ganglion cells, retinal thicknesses, and VEGF production in an experimental model of diabetes

Review

Association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V polymorphisms with retinal angiomatous proliferation compared with typical age-related macular degeneration: a meta-analysis

Review

Congenital cranial dysinnervation disorders

Original Paper

Surgical exploration in persistent inferior oblique overactions

Original Paper

Allogenic cultivated limbal stem cell transplantation versus cadaveric keratolimbal allograft in ocular surface disorder: 1-year outcome

Original Paper

Evaluating the growth of eyelid lesions: comparison of clinical evaluation and a software-based model